Advances in™ Congenital Adrenal Hyperplasia: Investigating the Impact of Emerging Agents
February 10, 2023
February 10, 2024
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grant from Neurocrine Biosciences, Inc.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This educational activity is directed toward endocrinologists, pediatricians, primary care clinicians, nurse practitioners, physician assistants, registered nurses, and other health care practitioners involved in the management of patients with CAH.
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of congenital adrenal hyperplasia (CAH), with a forward-looking perspective on how new and novel agents might impact clinical practice. The essentials of disease classification and clinical trial data, current and emerging treatment strategies, and management of CAH from infancy to adulthood will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.
Upon completion of this activity, participants should be better able to:
- Discuss the burden of CAH on patients
- Apply guideline recommendations for the management of patients with CAH
- Evaluate clinical trial data for emerging agents for the treatment of CAH
Adina Turcu, MD, MS
University of Michigan
Ann Arbor, Michigan
Perrin White, MD
Professor of Pediatrics
UT Southwestern Medical Center
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.
Adina Turcu, MD, MS, has no relevant financial relationships with ineligible companies.
- Perrin White, MD
- Grant/Research Support: Neurocrine, Diurnal
- Consultant: Neurocrine, Crinetics, Eton
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.